Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Appili Touts Non-Dilutive Grants as Cash Burn Outpaces Micro-Cap Equity Raises

By The Northwire Desk — AI Analysis Mar 30, 2026 · 07:19 APLI · 0.02 APPILI THERAPEUTICS INC. J
Executive Summary
  • Appili Therapeutics announced its exhibition at the World Vaccine Congress Washington (March 31 – April 2, 2026) to network with government agencies, vaccine experts, and potential collaborators.
  • The release highlights a previously announced US$40 million NIAID contract for the VXV-01 fungal vaccine and introduces a US$11.7 million U.S. Air Force Academy award for the ATI-1701 tularemia vaccine.
  • Management provided brief updates on commercial product LIKMEZ (recently relaunched in the U.S.) and ATI-1801 (Phase 3 efficacy demonstrated for leishmaniasis).
  • The stated objective is to leverage the conference to secure additional non-dilutive government funding and advance partnership discussions.
Material Impact
  • The announcement is promotional and recycles funding figures already disclosed in late 2025. The US$11.7 million Air Force award is newly highlighted but represents milestone-based government funding, not immediate cash.
  • No new clinical data, regulatory approvals, commercial revenue milestones, or binding partnership agreements were announced.
  • Given the company’s micro-cap valuation and historically low cash balance, a conference attendance notice does not alter the fundamental liquidity position or near-term operational trajectory.
  • The market has already priced in the US$40 million NIAID award, as evidenced by the stock’s return to its pre-announcement trading range.
APLI · Price
Company Overview
  • Appili Therapeutics is a clinical-stage biotechnology company focused on developing vaccines and therapeutics for infectious diseases and biodefense.
  • Flagship project: VXV-01, a dual-antigen vaccine targeting invasive fungal infections (Candida albicans, C. auris), backed by a US$40 million NIAID contract covering IND-enabling work and Phase 1 trials.
  • Secondary pipeline includes ATI-1701 (tularemia vaccine), ATI-1801 (topical paromomycin for cutaneous leishmaniasis), and LIKMEZ (commercialized oral metronidazole suspension generating royalties and milestone payments).
Read the original news release →

More from APPILI THERAPEUTICS INC. J

Jun 26, 2026 · 18:29

Pre-revenue biotech burns through cash, relies on distant government milestones while facing immediate going-concern liquidity crunch.

Earnings Feb 18, 2026 · 07:19

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

Financings Feb 12, 2026 · 18:15

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

Earnings Dec 18, 2025 · 18:34

Appili closes $177,500 first tranche of placement

Financings Dec 18, 2025 · 07:31

Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Financings Nov 13, 2025 · 17:21

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

Production / Operations